VNAR-Based BAFF Antagonists for Targeted B-Cell Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic monoclonal antibodies for treating autoimmune diseases and B-cell malignancies have limitations such as restricted antigen activity, poor tissue penetration, unwanted effector functions, high manufacturing costs, and product instability, necessitating the development of more effective BAFF antagonists.
Innovation Solution
The development of VNAR-derived BAFF antagonist compounds with high specificity and affinity for BAFF, comprising specific binding moieties with defined amino acid sequences, which compete with native BAFF ligands to inhibit BAFF/BAFF-R interaction, allowing for targeted B-cell depletion and modulation of autoimmune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic monoclonal antibodies are used to treat autoimmune diseases and B-cell malignancies, then antigen binding capability is achieved, but manufacturing costs increase and product stability decreases
Solution Approach 1:
The patent segments the conventional monoclonal antibody structure into individual VNAR domains derived from shark heavy-chain-only antibodies. Each VNAR contains a single variable domain that can independently bind antigens, eliminating the need for complex heavy and light chain assemblies. This segmentation simplifies manufacturing while maintaining binding capability.
Solution Approach 2:
The patent extracts only the essential antigen-binding variable domain (VNAR) from the complete monoclonal antibody structure. By taking out just the functional binding portion and removing the complex constant regions and pairing requirements, the invention achieves antigen binding capability with simplified production and improved stability.
2Reliability
If therapeutic monoclonal antibodies are used, then antigen binding capability is achieved, but tissue penetration ability decreases
Solution Approach 1:
The patent extracts only the compact variable domain (VNAR) from the full antibody structure, removing the extensive constant regions and inter-chain connections. This extraction results in a smaller molecular entity that can more effectively penetrate tissues while retaining the essential antigen-binding function.
Solution Approach 2:
By segmenting the antibody into individual VNAR domains, the patent creates smaller, more maneuverable binding units that can navigate through tissue barriers more efficiently than full-sized monoclonal antibodies.
3Reliability
If conventional monoclonal antibodies are used, then therapeutic effect is achieved, but unwanted effector functions occur
Solution Approach 1:
The patent takes out only the antigen-binding VNAR domain and omits the constant regions that mediate effector functions such as complement activation and Fc receptor engagement. This extraction allows therapeutic effect through antigen blocking while eliminating unwanted effector functions.
Solution Approach 2:
The patent applies local quality by designing VNARs that perform only the local function of antigen binding without the broader effector functions. Each VNAR is optimized for specific antigen recognition while lacking the constant region properties that would trigger unwanted immune responses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These VNAR-based BAFF antagonists demonstrate potent binding and blocking capabilities, effectively inhibiting BAFF-induced B-cell proliferation and survival, offering improved therapeutic and diagnostic benefits over existing antibodies, particularly in autoimmune diseases and B-cell-related disorders.
Implementation Method 1
VNAR single chain antibodies derived from nurse shark that bind to BAFF
Data Source
AI summary
The present invention relates to peptide antagonists that bind with high specificity and affinity to B-Lymphocyte stimulator (“BAFF”), thereby antagonizing BAFF receptor (“BAFF-R”) signaling. The invention more specifically relates to VNAR single chain antibodies derived from nurse shark that bind to BAFF, BAFF antagonist compounds and compositions comprising a BAFF specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo B cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete B cells, such as in autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) or multiple sclerosis (MS), and in certain hematological cancers, including lymphomas, leukemias and myelomas.